Tenderwize
Retour à la recherche

Open House Biologics Discount Agreement for Lutropin alfa / Follitropin alfa

Techniker Krankenkasse·Hamburg, Germany·Deadline May 30, 2027 · 277 days left·Open·Supplies
Inscrivez-vous pour sauvegarderOpen documents
Titre original de l'avis

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2025-09 - Lutropin alfa / Follitropin alfa (Wirkstoffkombination)

62/100

Score d'opportunité

Needs reviewMedium complexity
SuppliesOpen
Pourquoi ce score ?

Opportunité

62 / 100

Complexité

58 / 100

Facteurs de risque

Portal submission is not allowed; contracts must be submitted by email with qualified electronic signature or by post...

Only pharmaceutical undertakings meeting the AMG and authorisation requirements may participate.

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Supplies contract
  • 1 lot
  • Duration until May 2027
  • Supply-related Open House discount agreements for pharmaceutical products.
  • Product scope: Lutropin alfa / Follitropin alfa combination.
Afficher le résumé complet

This is an Open House supply arrangement by Techniker Krankenkasse (with HEK and hkk listed as participating buyers) for pharmaceutical products, specifically the Lutropin alfa / Follitropin alfa combination. The contract is non-exclusive, with uniform terms and no individual negotiations. The term is up to 24 months from 2025-06-01 and ends no later than 2027-05-31. Submission is not via the portal; contracts must be sent by email with qualified electronic signature or by post. No contract value is stated.

Risques

Portal submission is not allowed; contracts must be submitted by email with qualified electronic signature or by post...

Only pharmaceutical undertakings meeting the AMG and authorisation requirements may participate.

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal products.
  • Applicant must have its seat in the AMG territory, another EU Member State, or another EEA state.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal products or otherwise be entitled to place them on the market in its own name.

Acheteur

Localisation

Hamburg, DEU

Identifiant

992-80116-93

Activité

Health

Lots (1)

LOT-0001

Open House Biologics Discount Agreement for Lutropin alfa / Follitropin alfa

Single lot covering discount agreements under Section 130a(8) SGB V for the Lutropin alfa / Follitropin alfa medicinal product combination. The notice states the arrangement is open to all suitable pharmaceutical companies meeting the stated conditions, with no exclusivity and no individual negotiation. Scope and eligibility details are in the participation and contract documents.

SuppliesEU fundedElectronic submission

Localisation

DE600, Germany

Durée

May 2025 - May 2027

Catégorie

Pharmaceutical products

Date limite

Deadline May 30, 2027

Détails de la procédure

Date de publication
22 Apr 2025
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
262656-2025

Documents (1)

Document de consultation 1

Appels d'offres similaires

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3